Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022)
Enliven Therapeutics (ELVN) posted Operating Leases of $2.0 million for Q1 2022, up 384.48% sequentially from $406000.0 in Q4 2021, and up 233.39% YoY from $590000.0 in Q1 2021.
Enliven Therapeutics (ELVN) Operating Leases (2021 - 2022) Analysis & Trends
Enliven Therapeutics has reported Operating Leases for 2 years, with the latest figure at $2.0 million in Q1 2022.
- Quarterly Operating Leases rose 233.39% year-over-year to $2.0 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $2.0 million (up 233.39% YoY) and the FY2021 annual result came in at $406000.0, changed N/A from the prior year.
- Operating Leases improved to $2.0 million in Q1 2022 per ELVN's latest filing, from $406000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $2.0 million in Q1 2022 and troughed at $406000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 406,000.00 |
| Sep 30, 2021 | 466,000.00 |
| Jun 30, 2021 | 528,000.00 |
| Mar 31, 2021 | 590,000.00 |